Skip to content

Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers ( NEUROPSY-HEU )

Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04108728
Acronym
NEUROPSY-HEU
Enrollment
32
Registered
2019-09-30
Start date
2019-11-19
Completion date
2024-03-05
Last updated
2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Executive Dysfunction, Exposure During Pregnancy, HIV Infections, Neurophysiologic Abnormality

Brief summary

Main objective: to evaluate the executive functioning of the HIV exposed uninfected children (HEU) versus children from the same socio-economic and cultural environment, not infected or affected by HIV. Secondary objective (s): to evaluate Intellectual Quotient, Child development, Behavior, Language and investigate link between executive functioning disorders, exposure to ARVs, HIV and family environment.

Detailed description

The objective of the study is the exploration of executive functions (EF) and screening for neurodevelopment and learning disorders in children born to HIV-infected mothers, exposed to the virus and to antiretrovirals (ARVs). The evaluation of the executive functioning will be done by the score obtained at the preschool BRIEF for patients and control group issued from questionnaires filled by the mothers of the cases and the mothers of the controls, with matching on age, sex, level of parental education and socio-economic and cultural environment. Within the group of exposed children, factors associated with executive dysfunction including HIV infection, antiretroviral exposure, maternal socio-demographic data, sociocultural and environmental level will be investigated. Evolution of the scores between J0, M12 and M24 will be compared within the group of exposed children. Compared with a control group, the child's intelligence quotient, overall development, behavior and language will be compared at each follow-up time (D0, M12 and M24).

Interventions

DIAGNOSTIC_TESTBRIEF SCORE AT INCLUSION

BRIEF SCALE evaluation

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 3 Years
Healthy volunteers
Yes

Inclusion criteria

* experimental: * HIV-positive children born to mothers living with HIV antiretrovirals during pregnancy and in the neonatal period, aged 3 years +/- 3 months on the date of inclusion. * Parents mastering the French. * control: * children, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, no infected or affected by HIV. * Parents mastering French.

Exclusion criteria

* great prematurity (28-32 weeks) * genetic anomaly

Design outcomes

Primary

MeasureTime frameDescription
evaluate the executive function of children HEUinclusionBehaviour rating inventary of executive function (BRIEF) preschool version score

Secondary

MeasureTime frameDescription
Intellectual quotientat INCLUSION, 12 months after inclusion, 24 months after inclusionWechsler tests score
functional developmentat INCLUSION, 12 months after inclusion, 24 months after inclusionage and stage questionnaires score
behaviourat INCLUSION, 12 months after inclusion, 24 months after inclusionStrengths and Difficulties Questionnaire score
language12 months after inclusion,language dysfunction scale score

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026